Loading
A phase 3 trial of Bendamustine, Idelalisib, Rituximab and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors is a phase 3 interventional study registered as NCT06846671 by BeOne Medicines, with 250 participants planned, started 2025-04-10 and due to reach its primary completion in 2028-05-15. Interventions recorded: Tacabrutideg, Bendamustine, Idelalisib, Rituximab and Venetoclax.
Shares Idelalisib, Bendamustine, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Venetoclax, Rituximab and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.